Category Archives: Stem Cell Human Trials

GAITHERSBURG, MD--(Marketwired - May 6, 2013) - Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that the Company will release financial results for the three-month period ended March 31, 2013, after the close of the market on Thursday, May 9, 2013. Martin Rosendale, Chief Executive Officer, will host a conference call beginning at 8:00am Eastern time on Friday, May 10, 2013 to discuss the first quarter results and to answer questions, Conference Call & Webcast Friday, May 10, 2013 @ 8:00am Eastern/5:00am PacificDomestic dial in: 866-953-6857 International: 617-399-3481 Passcode: 19959894 Webcast: http://www.cytomedix.com Replays - Available through May 26, 2013 Domestic: 888-286-8010 International: 617-801-6888 Passcode: 23997367 About Cytomedix:Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for orthopedics and wound care with a pipeline of adult stem cell therapies for tissue repair. The Company markets the AutoloGel System, a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds and the Angel Concentrated Platelet Rich Plasma System, a blood processing device and disposable products used for the separation of whole blood or a mixture of blood and … Continue reading →

Washington, May 5 (ANI): UC San Francisco researchers have discovered that a key type of human brain cell developed in the laboratory grows seamlessly when transplanted into the brains of mice. The breakthrough raises hope that these cells might one day be used to treat people with Parkinson's disease, epilepsy, and possibly even Alzheimer's disease, as well as and complications of spinal cord injury such as chronic pain and spasticity. "We think this one type of cell may be useful in treating several types of neurodevelopmental and neurodegenerative disorders in a targeted way," said Arnold Kriegstein, MD, PhD, director of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF and co-lead author on the paper. The researchers generated and transplanted a type of human nerve-cell progenitor called the medial ganglionic eminence (MGE) cell. Development of these human MGE cells within the mouse brain mimics what occurs in human development, they said. Kriegstein sees MGE cells as a potential treatment to better control nerve circuits that become overactive in certain neurological disorders. Unlike other neural stem cells that can form many cell types - and that may potentially be less controllable as a consequence - … Continue reading →

San Diego, CA (PRWEB) May 02, 2013 Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Robert Sullivan, PhD, dean of the Rady School of Management at the University of California, San Diego (UC San Diego) has agreed to join the Companys Business Advisory Board. Dr. Sullivan is an expert on entrepreneurship, knowledge management and operations management. As an Advisor, Dean Sullivans specific focus will be Stemedicas newly formed Cardiology Division which aims to advance Stemedicas national and international clinical trials in chronic heart failure, acute myocardial infarct and other cardiac conditions. Within this Division, Dr. Sullivan will assist the Company as a liaison between not only the San Diego biotech and business communities, but with organizations worldwide. As the founding dean of the Rady School of Management, Dr. Sullivan has increased the schools brand in San Diego and throughout the world. He has successfully recruited top-tier faculty from universities such as the University of Chicago, Massachusetts Institute of Technology (MIT), New York University, Northwestern, Princeton, Stanford, the Wharton School and Yale. In 2011, Dr. Sullivan was elected vice chair-chair elect of the Association to Advance Collegiate Schools of Business (AACSB … Continue reading →

GAITHERSBURG, MD--(Marketwired - May 2, 2013) - Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that AutoloGel will be featured in oral and poster presentations at the Symposium on Advanced Wound Care (SAWC), that is being held in Denver, Colorado on May 1- 5, 2013. Dr. Caroline Fife, Chief Medical Officer of Intellicure and Medical Director at the St. Luke's Episcopal Hospital The Woodlands Center for Wound Healing, will deliver the oral presentation. Presentation Details Time: Saturday, May 5, 2013 from 4:30pm-5:30pm Abstract #: Oral - 40.4 Poster - CR-23 Title: Harnessing Electronic Medical Record Capabilities for Prospective Clinical Research: The Platelet Rich Plasma (PRP) Registry for Coverage with Evidence Development (CED) Location: Colorado Convention Center, Denver, Colorado Dr. Fife's oral presentation will outline the benefits of the EHR (electronic health record) system that is being used in the CED (Coverage with Evidence Development) program for AutoloGel.An EHR system with structured language has been customized to automatically perform the acquisition of data and verification of source in both the randomized trial and non-randomized cohort trials that make up the AutoloGel CED program. Only wound centers utilizing this EHR … Continue reading →

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) announced today that its Senior Vice President and Chief Operating Officer, Robert W. Peabody, will reassume the additional role of Chief Financial Officer on May 10, 2013. BioTimes current Chief Financial Officer, Peter S. Garcia, has resigned his position with BioTime and its subsidiaries effective May 10, 2013. Mr. Garcia is leaving BioTime on an amicable basis to become the chief financial officer of a larger public company located in another state. Mr. Peabody previously served as BioTimes Chief Financial Officer in 2010 and 2011. Mr. Peabody has worked in the financial management area throughout his career. His experience includes public accounting with Ernst & Young, and as a financial executive for a Fortune 500 specialty chemical manufacturer, and as Vice President of a public biotechnology company. About BioTime, Inc. BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary PureStem cell lines, HyStem hydrogels, culture … Continue reading →

Public release date: 28-Apr-2013 [ | E-mail | Share ] Contact: Hilary Glover hilary.glover@biomedcentral.com 44-020-319-22370 BioMed Central Injection of human stem cells into mice with tumors slowed down tumor growth, finds research published in BioMed Central's open access journal Stem Cell Research & Therapy. Human mesenchymal stem cells (MSC), isolated from bone marrow, caused changes in blood vessels supplying the tumor, and it is this modification of blood supply which seems to impact tumor growth. The use of stem cells in treating cancer has been controversial, with some studies finding that stem cells force tumors to enter programmed cell death. However other studies find that stem cells actually promote tumor growth by inducing infiltration of new blood vessels. In attempting to sort out this puzzle researchers from INSERM groups at Universit Joseph Fourier in collaboration with CHU de Grenoble investigated the impact of MSC on already established subcutaneous or lung metastasis in mice. For both the subcutaneous and lung tumors, injection of MSC reduced cell division, consequently slowing the rate of tumor growth. Part of the mode of action of stem cells therefore appears to be due to with angiogenesis, but the mechanism behind this is still unclear. Claire Rome … Continue reading →

Washington, April 26 (ANI): Harvard researchers have discovered a hormone that holds promise for a dramatically more effective treatment of type 2 diabetes, a metabolic illness afflicting millions of people. The researchers at the Harvard Stem Cell Institute (HSCI) believe that the hormone might also have a role in treating type 1, or juvenile, diabetes. The hormone, called betatrophin, causes mice to produce insulin-secreting pancreatic beta cells at up to 30 times the normal rate. The new beta cells only produce insulin when called for by the body, offering the potential for the natural regulation of insulin and a great reduction in the complications associated with diabetes, the leading medical cause of amputations and non-genetic loss of vision. The researchers who discovered betatrophin, HSCI co-director Doug Melton and postdoctoral fellow Peng Yi, caution that much work remains to be done before it could be used as a treatment in humans. But the results of their work, which was supported in large part by a federal research grant, already have attracted the attention of drug manufacturers. "If this could be used in people," said Melton, Harvard's Xander University Professor and co-chair of the University's Department of Stem Cell and Regenerative Biology, … Continue reading →

GAITHERSBURG, MD--(Marketwired - Apr 26, 2013) - Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that Martin Rosendale, the Company's Chief Executive Officer, will present at the 12th Annual Needham Healthcare Conference, on Wednesday, May 1, 2013 in New York. Presentation Details Time: Wednesday, May 1 at 11:20am Eastern / 8:20am Pacific Room: Ambassador Room Location: Westin Grand Central Hotel, 212 E 42nd St, New York, NY A live webcast of the presentation may be accessed through the Company's website at http://www.cytomedix.com. A replay of the webcast will be available for one week following the conference. About the Needham Healthcare ConferenceNeedham & Company's 12th Annual Healthcare Conference will take place in New York on April 30th and May 1st. This is a forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors. This conference is by invitation only. About Cytomedix: Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for orthopedics and wound care with a pipeline of adult stem cell therapies … Continue reading →

Editor's Choice Main Category: Diabetes Article Date: 26 Apr 2013 - 9:00 PDT Current ratings for: Hormone Dramatically Increases Insulin Production, Possible Diabetes Breakthrough 4.25 (16 votes) 4.2 (5 votes) The authors wrote that betatrophin might also help patients with type 1 diabetes, or juvenile diabetes when they are first diagnosed. In animal experiments the researchers found that betatrophin caused laboratory mice to produce beta cells at up to 30 times the normal rate. Beta cells are the insulin-secreting cells in the pancreas - put simply, beta cells produce insulin. These new beta cells only produce insulin when the body requires it. The scientists explained that this breakthrough could mean that type 2 diabetes patients may have a natural regulation of insulin, plus a considerable reduction in diabetes-related complications. Diabetes is a major cause of amputations and non-genetic loss of vision. HSCI Co-Director Doug Melton and postdoctoral fellow Peng Yi, who both discovered betatrophin, stressed that a great deal of work remains to be done before trying the hormone out on humans. They added that their work so far, which was mainly funded by a federal research grant, has already attracted the attention of pharmaceutical and biotech companies. Doug Melton, … Continue reading →

Betatrophin sparks the proliferation of pancreatic cells in mice, which are found in the islet of Langerhans (shown here). ROBERT MARKUS/SCIENCE PHOTO LIBRARY Biologists have found a hormone in the liver that spurs the growth of insulin-secreting cells in the pancreas, a discovery they hope will lead to new treatments for diabetes. A team led by Douglas Melton, co-director of the Harvard Stem Cell Institute in Cambridge, Massachusetts, identified the hormone, betatrophin, by inducing insulin resistance in mice using a peptide that binds to insulin receptors. That caused the animals' insulin-secreting pancreatic cells to proliferate. The researchers then searched for genes that showed increased activity, zeroing in on one that they were able to link to betatrophin production. Further experiments showed that 8-week-old mice injected with betatrophin showed showed an average 17-fold rise in the replication of their insulin-secreting pancreatic cells, the researchers report in Cell1. Betatrophin is also found in the human liver, the team says. Its rare that one discovers a new hormone, and this one is interesting because its so specific, says Melton. It works only on cellsand its so robust and so potent. Pancreatic cells replicate rapidly during embryonic and neonatal stages in both mice and … Continue reading →